The citicholinage study: Citicoline plus cholinesterase inhibitors in aged patients affected with Alzheimer’s disease study 

In a retrospective multicenter case-control study from 2017, 448 patients with Alzheimer’s disease were treated either with an acetylcholinesterase inhibitor (AChEI) drug only, or the AChEI drug plus 1000 mg of citicoline daily for nine months. There was a significant increase in Mini-Mental State Examination scores in patients given citicoline at the three-month mark and between the three- and nine-month mark. Researchers concluded that the combined administration may slow the progression of Alzheimer’s disease.   

References:

Gareri, P., Castagna, A., Cotroneo, A. M., Putignano, D., Conforti, R., Santamaria, F., Marino, S., & Putignano, S. (2017). The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer’s Disease Study. Journal of Alzheimer’s disease : JAD, 56(2), 557–565. https://doi.org/10.3233/JAD-160808